Physician profile
Jesse Arthur
NPI 1710407937
$980.49
in general payments reported to CMS, 2019-2025
15 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $34.13 · 2024: $257 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.36 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $143.69 | 2019-2025 | Farxiga, Airsupra |
| Portola Pharmaceuticals, LLC | $130.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $107.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.86 | 2019-2020 | |
| Pfizer INC. | $67.13 | 2019-2024 | |
| Exact Sciences Corporation | $47.38 | 2024-2025 | Cologuard Collection Kit |
| La Jolla Pharmaceutical Company | $43.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.52 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $33.44 | 2024-2025 | Rexulti, Nuedexta |
| Phathom Pharmaceuticals, INC. | $31.07 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.36 | 2024 | Caplyta |
| Dexcom, INC. | $16.70 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.30 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $16.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Arthur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.